Ernst-guenter Afting - Net Worth and Insider Trading
Ernst-guenter Afting Net Worth
The estimated net worth of Ernst-guenter Afting is at least $89,623 dollars as of 2024-05-04. Ernst-guenter Afting is the Director of Sequenom Inc and owns about 37,499 shares of Sequenom Inc (SQNM) stock worth over $89,623. Details can be seen in Ernst-guenter Afting's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ernst-guenter Afting has not made any transactions after 2008-12-09 and currently still holds the listed stock(s).
Transaction Summary of Ernst-guenter Afting
Ernst-guenter Afting Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ernst-guenter Afting owns 3 companies in total, including Enanta Pharmaceuticals Inc (ENTA) , Sorrento Therapeutics Inc (SRNE) , and Sequenom Inc (SQNM) .
Click here to see the complete history of Ernst-guenter Afting’s form 4 insider trades.
Insider Ownership Summary of Ernst-guenter Afting
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ENTA | Enanta Pharmaceuticals Inc | 2013-03-20 | director |
| SRNE | Sorrento Therapeutics Inc | 2010-02-05 | director |
| SQNM | Sequenom Inc | 2013-06-11 | director |
Ernst-guenter Afting Latest Holdings Summary
Ernst-guenter Afting currently owns a total of 1 stock. Ernst-guenter Afting owns 37,499 shares of Sequenom Inc (SQNM) as of December 9, 2008, with a value of $89,623.
Latest Holdings of Ernst-guenter Afting
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SQNM | Sequenom Inc | 2008-12-09 | 37,499 | 2.39 | 89,623 |
Holding Weightings of Ernst-guenter Afting
Ernst-guenter Afting Form 4 Trading Tracker
According to the SEC Form 4 filings, Ernst-guenter Afting has made a total of 0 transactions in Sequenom Inc (SQNM) over the past 5 years. The most-recent trade in Sequenom Inc is the sale of 6,300 shares on December 9, 2008, which brought Ernst-guenter Afting around $104,076.
Insider Trading History of Ernst-guenter Afting
- 1
Ernst-guenter Afting Trading Performance
GuruFocus tracks the stock performance after each of Ernst-guenter Afting's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ernst-guenter Afting is 108.6%. GuruFocus also compares Ernst-guenter Afting's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ernst-guenter Afting within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ernst-guenter Afting's insider trading performs compared to the benchmark.
Performance of Ernst-guenter Afting
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 8.6 | | | | | |
| Relative Return to S&P 500(%) | 6 | | | | | |
Ernst-guenter Afting Ownership Network
Ernst-guenter Afting Owned Company Details
What does Enanta Pharmaceuticals Inc do?
Who are the key executives at Enanta Pharmaceuticals Inc?
Ernst-guenter Afting is the director of Enanta Pharmaceuticals Inc. Other key executives at Enanta Pharmaceuticals Inc include Chief Medical Officer Scott T. Rottinghaus , Sr. VP & Business Dev. Brendan Luu , and Sr. VP & New Product Dev. Tara Lynn Kieffer .
Enanta Pharmaceuticals Inc (ENTA) Insider Trades Summary
Over the past 18 months, Ernst-guenter Afting made no insider transaction in Enanta Pharmaceuticals Inc (ENTA). Other recent insider transactions involving Enanta Pharmaceuticals Inc (ENTA) include a net sale of 65,142 shares made by Jay R. Luly , a net sale of 16,337 shares made by Yat Sun Or , and a net sale of 12,852 shares made by Paul J Mellett .
In summary, during the past 3 months, insiders sold 0 shares of Enanta Pharmaceuticals Inc (ENTA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 116,822 shares of Enanta Pharmaceuticals Inc (ENTA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 116,822 shares.
Enanta Pharmaceuticals Inc (ENTA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Enanta Pharmaceuticals Inc Insider Transactions
Ernst-guenter Afting Mailing Address
Above is the net worth, insider trading, and ownership report for Ernst-guenter Afting. You might contact Ernst-guenter Afting via mailing address: C/o Sorrento Therapeutics, Inc., 6042 Cornerstone Ct., Suite B, San Diego Ca 92121.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
